Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ FGL1 Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA519204
Description
This antibody is predicted to react with bovine, canine, mouse and rat based on sequence homology. This antibody is tested in Peptide ELISA: antibody detection limit dilution 16,000.
Fibrinogen-like 1 is a member of the fibrinogen family. This protein is homologous to the carboxy terminus of the fibrinogen beta- and gamma- subunits which contains the four conserved cysteines of fibrinogens and fibrinogen related proteins. However, this protein lacks the platelet-binding site, cross-linking region and a thrombin-sensitive site which are necessary for fibrin clot formation. This protein may play a role in the development of hepatocellular carcinomas. Four alternatively spliced transcript variants encoding the same protein exist for this gene.
Specifications
FGL1 | |
Polyclonal | |
Unconjugated | |
FGL1 | |
Fgl1; fibrinogen like 1; fibrinogen-like 1; fibrinogen-like protein 1; Fibrinogen-related protein 1; fibronigen-like protein 1; Frep1; Hepassocin; hepatocellular carcinoma-related sequence; hepatocyte-derived fibrinogen-related protein 1; HFREP1; HFREP-1; HP-041; HPS; Lfire1; LFIRE-1; Liver fibrinogen-related protein 1; Liver fibrinogen-related protein-1; Mfire1; Mfire-1; Mfrep-1; MGC12455; OTTHUMP00000122468 | |
Goat | |
Ammonium Sulfate Precipitation | |
RUO | |
2267 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot | |
0.5 mg/mL | |
TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
Q08830 | |
FGL1 | |
Synthetic peptide sequence (ETRVKQQQVKIKQ) corresponding to the internal amino acids of FGL1 (aa 41-54). | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction